Related Experiment Videos
Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired
A Ohara1, S Kojima, N Hamajima
1Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology.
Insights
Children treated with both cyclosporin (CSA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) for aplastic anemia (AA) showed an increased risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). This occurred earlier than previously reported.
Area of Science:
- Pediatric Hematology
- Oncology
- Clinical Research
Background:
- Acquired aplastic anemia (AA) treatment has improved, but late complications like myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) are emerging.
- Understanding the long-term risks associated with specific therapies in pediatric AA is crucial.
Purpose of the Study:
- To investigate the incidence of MDS/AML in children with severe acquired AA.
- To identify potential risk factors, particularly therapeutic modalities, associated with MDS/AML development.
Main Methods:
- Retrospective analysis of 167 children diagnosed with severe acquired AA.
- Comparison of MDS/AML development rates among children treated with cyclosporin (CSA) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF), or bone marrow transplantation (BMT).
Main Results:
- 11 out of 50 children treated with both CSA and rhG-CSF developed MDS/AML, with 8 cases occurring within 36 months of AA diagnosis.
- High-dose rhG-CSF (exceeding 10 microg/kg/d) and prolonged therapy (over 1 year) were noted in several affected children.
- Monosomy 7 was observed in 10 of the 11 children diagnosed with MDS.
- No MDS/AML cases were reported in children treated with CSA or rhG-CSF alone, or those who underwent BMT.
Conclusions:
- Combination therapy with CSA and rhG-CSF may be associated with an increased and earlier onset of MDS/AML in pediatric severe acquired AA.
- Further investigation into the specific roles of CSA and rhG-CSF in the pathogenesis of MDS/AML is warranted.
- A controlled clinical trial is necessary to confirm these findings and guide therapeutic strategies.
Abstract:
The improved outcome of acquired aplastic anemia (AA) has revealed later complications, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We retrospectively analyzed 167 children with severe acquired AA. Eleven of 50 children treated with cyclosporin (CSA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) developed MDS/AML; 8 of these were within 36 months of the diagnosis of AA, much earlier than previous reports. Six of the 11 children received rhG-CSF exceeding 10 microg/kg/d, and 9 received rhG-CSF therapy for over 1 year. Ten children showed monosomy 7 at diagnosis of MDS. All of the 11 children were administered both CSA and rhG-CSF. There was no development of MDS/AML among 41 children treated with either CSA or rhG-CSF or among 48 children who underwent bone marrow transplantation. A well-controlled clinical trial is warranted to determine whether therapeutic modalities affect the development of MDS/AML in children with severe acquired AA.